MicroRNA-362 Inhibits Cell Proliferation and Invasion by Directly Targeting SIX1 in Colorectal Cancer

Wan, Jin'e; Yang, Jian; Qiao, Cuixia; Sun, Xiaomei; Di, Aiting; Zhang, Lize; Wang, Dandan; Zhao, Gang

doi:10.3349/ymj.2019.60.5.414

Cited by 8 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, it is vital to control the occurrence and development of CRC to better manage the substantial health burden. The incidence and mortality of CRC are increasing in China due to the aging population and advanced stages of the disease (5)(6)(7). Patients aged 75 years and over constitute a large proportion of new CRC cases (above 40%), and about 45% patients are in advanced stages when first diagnosed (8,9).…”

Section: Introductionmentioning

confidence: 99%

The Chemokine CXCL7 Is Related to Angiogenesis and Associated With Poor Prognosis in Colorectal Cancer Patients

Jiang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveThe present study was designed to investigate the role of the chemokine CXCL7 in angiogenesis and explore its prognostic value in colorectal cancer (CRC).MethodsA total of 160 CRC patients who had undergone surgery were included in this study, and staged according to the guidelines of the AJCC, 7th Edition. Expression of CXCL7 and VEGF was detected by immunohistochemical (IHC) staining and divided into high and low expression subgroups. The correlation between CXCL7 and VEGF expression was evaluated by Spearman’s rank-correlation coefficient. Prognosis based on CXCL7 and VEGF was evaluated using the Cox proportional hazards regression model and a nomogram of 5-year overall survival (OS) time.ResultsCXCL7 was highly expressed in tumor tissues (65.63% vs 25.00% in paracancerous tissue, P < 0.001), as was VEGF. CXCL7 and VEGF expression correlated well with N and TNM stage cancers (all P < 0.001). Importantly, CXCL7 was positively correlated with VEGF expression in CRC tissues. CXCL7 was an independent predictor of poor OS of CRC patients (HR = 2.216, 95% CI: 1.069-4.593, P = 0.032), and co-expression of CXCL7 and VEGF of predicted poor OS of 56.96 months.ConclusionExpression of CXCL7 correlated with VEGF and was associated with poor clinical outcomes in CRC patients.

show abstract

Section: Introductionmentioning

confidence: 99%

The Chemokine CXCL7 Is Related to Angiogenesis and Associated With Poor Prognosis in Colorectal Cancer Patients

Jiang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…In addition, SIX1 was found to upregulate vascular endothelial growth factor-C (VEGF-C) expression to induce lymphangiogenesis and metastasis in BC mouse models [ 32 ]. Recent data suggest that several miRNAs including miR-362, miR-186-5p, and miR-188 target the 3ʹ untranslated regions (3ʹ UTRs) of the SIX1 mRNA to induce its degradation and inhibit its translation in several cancers [ 33–35 ]. Through bioinformatic analysis, we discovered putative miR-590-3p binding sites in the SIX1 3ʹ UTR.…”

Section: Introductionmentioning

confidence: 99%

Long non-coding RNA (LncRNA) CASC9/microRNA(miR)-590–3p/sine oculis homeobox 1 (SIX1)/NF-κB axis promotes proliferation and migration in breast cancer

Chang¹,

Zhang²,

Ye³

et al. 2021

Bioengineered

View full text Add to dashboard Cite

Long non-coding RNA (lncRNA)–microRNA–mRNA signaling axes have recently been shown to have a key role in the development of breast cancer (BC). In this study, we investigated how the cancer susceptibility candidate 9 (CASC9) gene affects the cell growth, invasion, migration, and apoptosis of BC cells. The levels of microRNA-590-3p (miR-590-3p), CASC9, and the sine oculis homeobox 1 (SIX1) gene were determined through qRT-PCR. We conducted cell counting kit-8 (CCK-8) assays to assess cell proliferation, transwell assays to detect cell migration/invasion, and flow cytometry to evaluate cell apoptosis. StarBase v2.0 was used to predict interactions between miR-590-3p and SIX1 or CASC9, and dual-luciferase reporter assays were used to verify these predictions. CASC9 protein was overexpressed in BC cells and tissues, while CASC9 knockdown inhibited BC cell growth, invasion, and migration and promoted apoptosis. Additionally, we verified that CASC9 competes for binding with miR-590-3p. Moreover, SIX1 was determined to be a target of miR-590–3p, and SIX1 expression was inhibited by miR-590-3p overexpression. CASC9 enhanced BC development by downregulating miR-590-3p and upregulating SIX1 during the activation of the NF-κB pathway. These data suggest that the CASC9/miR-590-3p/SIX1/NF-κB axis is involved in breast cancer progression, providing insight into the function of CASC9 in breast cancer development.

show abstract

“…Colorectal cancer (CRC) is one of the most common cancer in the digestive system worldwide, and the morbidity and mortality are at the forefront. Nowadays, CRC remains the most fatal cancer in China ( 1 – 4 ). According to the newly published cancer data report of the United States in 2017, the number of CRC patients and deaths were 135,430 and 50,260 in China, which ranked the top of the gastrointestinal cancer both in morbidity and mortality ( 3 ).…”

Section: Introductionmentioning

confidence: 99%

Serum Chemokine CXCL7 as a Potential Novel Biomarker for Obstructive Colorectal Cancer

Zhang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Due to the lack of typical symptoms and signs and sensitive indicators for early diagnosis of obstructive colorectal cancer (OCRC), it is critically needed to find new novel biomarkers to ameliorate the management of OCRC patients. In this study, 472 blood samples were collected and measured by enzyme-linked immunosorbent assay (ELISA) to investigate the value of serum chemokine ligand 7 (CXCL7) in diagnosis and prognosis for OCRC patients. The median concentrations of CXCL7 in non-OCRC and OCRC were both higher than that in controls (both P < 0.05). Importantly, the median serum concentration of CXCL7 in OCRC was also higher than that in non-OCRC (P < 0.001). In all OCRC patients, the area under the curve (AUC) of CXCL7 was 0.918 with a sensitivity of 86.54% and a specificity of 81.87%. Similarly, the AUC of CXCL7 was 0.684 when the diagnostic test was performed between OCRC and CRC patients. CXCL7 had a higher AUC than other markers. The concentration of CXCL7 in 40 postoperative OCRC patients was higher than normal people and lower than preoperative patients. The median survival time was 62.00 months and the 5-year overall survival (OS) rate of the patients was 51.80% in all 155 OCRC patients. Multivariate Cox proportional hazard regression model analysis showed that high CXCL7 in serum was independent factors associated with poor OS of OCRC patients (HR = 2.216, P = 0.032). These results demonstrate that serum CXCL7 may be a potential biomarker both in diagnosis and prognosis for OCRC patients.

show abstract

MicroRNA-362 Inhibits Cell Proliferation and Invasion by Directly Targeting SIX1 in Colorectal Cancer

Cited by 8 publications

References 38 publications

The Chemokine CXCL7 Is Related to Angiogenesis and Associated With Poor Prognosis in Colorectal Cancer Patients

The Chemokine CXCL7 Is Related to Angiogenesis and Associated With Poor Prognosis in Colorectal Cancer Patients

Long non-coding RNA (LncRNA) CASC9/microRNA(miR)-590–3p/sine oculis homeobox 1 (SIX1)/NF-κB axis promotes proliferation and migration in breast cancer

Serum Chemokine CXCL7 as a Potential Novel Biomarker for Obstructive Colorectal Cancer

Contact Info

Product

Resources

About